Summary
The study found significant correlations between the aMCC excretion rate and smoking dose indicators, confirming earlier findings of dose-dependent relationships in smokers. however, the background exposure to toluene is most likely too high to use SBMa as a biomarker for distinguishing various tobacco/nicotine product user groups. In contrast, EMa excretion was elevated in smokers, with a clear dose-response relationship, but its suitability as a biomarker to distinguish users is limited due to the elevated levels found in smokers compared to other groups. The study also found that urinary excretion of hEMa, 2-MhBMa, and SPMa was significantly higher in smokers on Day 3 compared to other groups, while DhBMa excretion was only significantly elevated in smokers compared to NU, EC, and NRT groups. Further investigation is required to better understand the potential of these biomarkers in distinguishing tobacco/nicotine product users.
Citation
Scherer G, Pluym N, Scherer M. Comparison of urinary mercapturic acid excretions in users of various tobacco/nicotine products. Drug testing and analysis. Published online September 26, 2022. doi:10.1002/dta.3372
